Sarepta Therapeutics Inc.

NASDAQ: SRPT · Real-Time Price · USD
62.70
0.30 (0.48%)
At close: May 01, 2025, 12:09 PM
0.48%
Bid 62.58
Market Cap 6.16B
Revenue (ttm) 1.9B
Net Income (ttm) 235.24M
EPS (ttm) 2.34
PE Ratio (ttm) 26.79
Forward PE 4.74
Analyst Buy
Ask 62.77
Volume 438,515
Avg. Volume (20D) 1,984,280
Open 62.45
Previous Close 62.40
Day's Range 60.53 - 64.00
52-Week Range 48.01 - 173.25
Beta 0.92

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 4, 1997
Employees 1,372
Stock Exchange NASDAQ
Ticker Symbol SRPT
Full Company Profile

Analyst Forecast

According to 22 analyst ratings, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is $167.5, which is an increase of 167.15% from the latest price.

Stock Forecasts

Next Earnings Release

Sarepta Therapeutics Inc. is scheduled to release its earnings on May 6, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
-6.18%
Sarepta Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
1 month ago
-9.36%
Sarepta Therapeutics shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform and lowered the price target from $161 to $87.